Toviaz Approval History
- FDA approved: Yes (First approved October 31st, 2008)
- Brand name: Toviaz
- Generic name: fesoterodine fumarate
- Dosage form: Extended Release Tablets
- Company: Pfizer Inc.
- Treatment for: Overactive Bladder
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Development History and FDA Approval Process for Toviaz
|Oct 31, 2008||Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.